News

SurModics paid $3 million in cash at closing and may pay up to an additional $6 million in cash upon the successful achievement of certain milestones. The acquisition

Most recently, Mr Leest was Arterial Remodeling Technologies’s (ART’s) COO since March 2008. Prior to joining ART, he was director of R&D and regulatory affairs since May 2003

In each of two in vitro models of hepatitis C virus (HCV) entry and replication, PRO 206 demonstrated potent inhibitory activity at concentrations that had no measurable effect

In this role, Ms Bielefeld-Sevigny will be responsible for driving expansion of the reagents portfolio for its bio-discovery business. Most recently, Ms Bielefeld-Sevigny, served as director of molecular

Under the terms of the agreement, Inverness will have co-exclusive worldwide distribution rights with PrognostiX in all countries except Italy and Russia. PrognostiX previously secured distributors in these

A Phase I study of CERE-110 indicated that a single administration of the therapy was well tolerated, though the study was too small to make a definitive statement

Under the collaboration agreement, Thermo Fisher Scientific will provide Genentech with small-interfering RNA (siRNA) design, stabilization, delivery and related RNA interference (RNAi) technologies from its RNAi Discovery and

This tranche brings the total series B financing to $154 million. New investor Nomura phase4 Ventures participated in the financing along with existing OncoMed investors. OncoMed investors include

Mr Forlenza and Mr Elkins will both report to Edward Ludwig, who will remain as chairman and CEO. John Considine will remain as vice chairman. As president, Mr